Contemporary outcomes of the Fontan operation: An Australian and New Zealand Fontan Registry study
Michael Daley, Igor E. Konstantinov, Supreet Marathe, Tim Hornung, Patrick Disney, Nelson Alphonso, Jelena Saundankar, Gavin Wheaton, Leeanne Grigg, Vishva Wijesekera, Ajay Iyengar, Julian Ayer, Rachael Cordina, Yves d’Udekem · 2026
Read Contemporary outcomes of the Fontan operation: An Australian and New Zealand Fontan Registry study by Michael Daley, Igor E. Konstantinov, Supreet Marathe, Tim Hornung, Patrick Disney, Nelson Alphonso, Jelena Saundankar, Gavin Wheaton, Leeanne Grigg, Vishva Wijesekera, Ajay Iyengar, Julian Ayer, Rachael Cordina, Yves d’Udekem (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13477081.txt.
Introduction
Michael Daley and thirteen co-authors report long-term results for a heart operation in children in a 2026 registry study. The Fontan operation reroutes blood for hearts born with one working pump chamber. Australia and New Zealand track these patients in a shared registry, which allows rare long-range follow-up.
Survival without transplant reached eighty-five percent at thirty years. Freedom from Fontan failure stood at three quarters over the same span. The study also tests whether the size of the surgical conduit matters. Over a thousand patients had recorded sizes, mostly in two common bands. Outcomes did not differ between smaller and larger conduits. Risk factors for late problems, from rhythm trouble to clots, are weighed across the cohort.
Catalog record
| CREATOR | Michael Daley, Igor E. Konstantinov, Supreet Marathe, Tim Hornung, Patrick Disney, Nelson Alphonso, Jelena Saundankar, Gavin Wheaton, Leeanne Grigg, Vishva Wijesekera, Ajay Iyengar, Julian Ayer, Rachael Cordina, Yves d’Udekem |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Contemporary outcomes of the Fontan operation: An Australian and New Zealand Fontan Registry study Authors: Michael Daley, Igor E. Konstantinov, Supreet Marathe, Tim Hornung, Patrick Disney, Nelson Alphonso, Jelena Saundankar, Gavin Wheaton, Leeanne Grigg, Vishva Wijesekera, Ajay Iyengar, Julian Ayer, Rachael Cordina, Yves d’Udekem Published: 2026 ABSTRACT ObjectiveWe sought to review the impact of extracardiac conduit size and risk factors on the long-term outcomes of the contemporary Fontan procedure: lateral tunnel and extracardiac conduits.MethodsData were collected from a binational registry. Composite outcome of late adverse events included death, transplant, Fontan failure, supraventricular tachycardia (SVT), thromboembolism, or pacemaker implantation.ResultsTransplant-free survival and freedom from Fontan failure was 85% (95% CI, 80%-89%) and 75% (95% CI, 70%-80%) at 30 years, respectively. Extracardiac conduit sizes were available in 1075 patients, with 18 mm (n = 596) and 20 mm (n = 355) being the most common. There was no difference in transplant-free survival, Fontan failure, or late adverse events between patients who received extracardiac conduits with smaller or larger conduits (≤18 mm vs ≥20 mm, P = .41, P = .50, and P = .27, respectively). Only 8 patients (<1%) underwent conduit upsizing during follow-up, all concurrently with another intervention. Lateral tunnel, isomerism, and fenestration were associated with sustained SVT on multivariable analysis (hazard ratio [HR], 2.0, P = .002; HR, 2.4, P < .001; HR, 1.7, P = .013, respectively). Only Fontan fenestration and isomerism were associated with the incidence of thromboembolic events (n = 161) on multivariable analysis (HR, 1.5, P = .021 and HR, 1.4, P = .025, respectively). Landmark analysis was performed from 16 years of age in patients without Fontan failure (n = 813). Transplant-free survival and freedom from Fontan failure were 87% (95% CI, 81%-91%) and 80% (95% CI, 72%-85%) at 20 years from this time point, respectively.ConclusionsDespite recent suggestions, extracardiac conduit sizes do not appear to affect long-term clinical outcomes. Patients with lateral tunnel have a greater incidence of sustained SVT, and Fontan fenestration may increase incidence of late adverse events. Freedom from Fontan failure between small (≤18 mm) and larger (≥20 mm) ECCs. Central MessageThe long-term outcomes of the Fontan operation remain excellent in the current era. The size of extracardiac conduit does not currently appear to be a risk factor for long-term clinical events. PerspectiveAs Fontan patients live longer, it behooves us to investigate if we are performing the best operation for our patients in the longer term. Recent concerns of deleterious effects from relatively undersized extracardiac conduits were unsupported by the clinical outcomes from our binational registry review. However, further insight may be gained by detailed assessment of liver function and fibrosis. Freedom from Fontan failure between small (≤18 mm) and larger (≥20 mm) ECCs. Central Message The long-term outcomes of the Fontan operation remain excellent in the current era. The size of extracardiac conduit does not currently appear to be a risk factor for long-term clinical events. Perspective As Fontan patients live longer, it behooves us to investigate if we are performing the best operation for our patients in the longer term. Recent concerns of deleterious effects from relatively undersized extracardiac conduits were unsupported by the clinical outcomes from our binational registry review. However, further insight may be gained by detailed assessment of liver function and fibrosis. The Fontan operation, described by Francis Fontan in 1971, was the culmination of decades of work on right heart bypass.1 The procedure provided the first viable option for sustainable univentricular circulation in patients with severe congenital cardiac abnormalities. From its conception to the end of the 20th century, there have been multiple advancements to the procedure in a bid to improve both the short- and long-term outcomes.2, 3, 4, 5, 6 The lateral tunnel (LT) was described by de Leval in 1988 and rapidly became the most frequently used technique until the turn of the millennium, when the extracardiac conduit (ECC) became the most favored technique, likely because of the potential for more favorable hemodynamics and reduced rate of late arrhythmias.3,4 In the Society of Thoracic Surgeons database, 82% of the Fontan operations performed between 2012 and 2022 were with ECCs.7 Recently, the benefit of the ECC has been questioned, with reports of superior early outcomes and decreased risk of late liver cirrhosis with the LT, with particular concerns over the relatively undersized ECC conduit in adulthood.8, 9, 10, 11 With these conflicting reports, there is no consensus of improved survival with either of these 2 techniques, and we wanted to investigate this comparative survival in large dataset. The Australia and New Zealand Fontan Registry (ANZFR) was established more than a decade ago and is currently the largest Fontan operation registry in the world.12, 13, 14 It collected clinical data for patients who received a Fontan operation in Australia and New Zealand and provided benchmark outcomes for patients with Fontan circulation worldwide. With more than a decade of registry development, we also sought to review the outcomes of the patients with Fontan circulation in Australia and New Zealand and assess the impact of our updated management of these patients. Methods Registry Design The ANZFR was created in 2008, and over the following 5 years data were collected on patients with Fontan circulation from all hospital databases and private cardiology practices across Australia and New Zealand.14 The exact design of the ANZFR has previously been described. Of note, patients with a Björk procedure were excluded from the registry. Ethics approval is granted by participating institutions and bi-nationally (RCH HREC 36260/ACSQHC-ARCR-189; February 15, 2012). Written consent was initially retrospectively sought, then prospectively, with an opt-out enrollment at the time of the Fontan operation. Because of the historical nature of the procedure, patients with atriopulmonary Fontan (n = 263) have their demographics described and then excluded from further analysis, with the exception of Fontan conversions. Definitions Preoperative hemodynamic characteristics, including moderate or greater atrioventricular (AV) valve regurgitation and moderate or greater (systemic) ventricular dysfunction, were derived from preoperative investigation reports, multidisciplinary conference and clinic letters, and operation reports. Early mortality was defined as death <30 days after the Fontan operation or before hospital discharge. Fontan failure was defined as the incidence of at least 1 of the following during follow-up: death, heart transplantation, Fontan conversion or takedown, New York Heart Association (NYHA) class III or IV symptoms, plastic bronchitis, or protein-losing enteropathy. Latest follow-up was defined as the last clinical encounter with the patient. Single-stage Fontan was defined as both caval connections performed in the same procedure. Prolonged pleural effusion was defined as pleural effusions requiring chest drain for ≥30 days, reintervention for effusions, or the presence of chylothorax for ≥30 days. Thromboembolic events included strokes, reversible ischemic neurologic deficits, transient ischemic attacks, pulmonary emboli, intracardiac thrombi, Fontan circuit or caval thrombi, shunt thrombi, and peripheral deep vein thrombi. Only post-Fontan thromboembolic events were included. Supraventricular tachycardias (SVTs) included atrial fibrillation, atrial flutter, atrioventricular nodal re-entry tachycardias, and other intra-atrial re-entry tachycardias. Only post-Fontan supraventricular tachyarrhythmias were included. Fontan fenestration was defined as fenestration creation at the time of Fontan operation. The size of fenestration was at surgeon discretion and not collected as part of this study. Similarly, fenestration patency was not routinely assessed during follow-up and was not